Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Inhibition

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule inhibitor with high selectivity for VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) under standardized in vitro kinase assay conditions (Xie et al., 2018). It robustly blocks VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation, outperforming legacy TKIs such as sunitinib and sorafenib (DOI). Anlotinib is orally bioavailable (28–77% in preclinical models), displays high plasma protein binding (93% in humans), and distributes extensively to tumor, lung, liver, kidney, and brain tissues (APExBIO). Safety evaluations reveal a high median lethal dose (LD₅₀ = 1735.9 mg/kg, 14-day oral, rat), with no significant organ or genetic toxicity at research-use concentrations (Xie et al., 2018). For anti-angiogenic research, Anlotinib hydrochloride enables precise modeling of tyrosine kinase signaling and tumor vascular dynamics.

Biological Rationale

Angiogenesis is a prerequisite for solid tumor growth and metastasis, typically activated once tumor volume exceeds ~1 mm³ (Xie et al., 2018). The process is orchestrated by growth factors such as VEGF, PDGF, and FGF, which bind to cognate receptor tyrosine kinases (RTKs), including VEGFR2, PDGFRβ, and FGFR1, on endothelial cells. Persistent, unregulated angiogenesis is a hallmark of cancer progression. Endothelial cells are genetically stable; thus, anti-angiogenic strategies targeting these cells are less prone to resistance than those targeting tumor cells (Xie et al., 2018). Multi-target TKI approaches offer improved efficacy by simultaneously modulating complementary pro-angiogenic pathways.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a low-molecular-weight, orally active inhibitor that binds the ATP-binding pocket of VEGFR2, PDGFRβ, and FGFR1 tyrosine kinases. This occupancy disrupts downstream ERK and Akt signaling pathways, leading to reduced endothelial cell proliferation, migration, and capillary tube formation. In cellular models (EA.hy 926, HUVEC), anlotinib blocks VEGF/PDGF-BB/FGF-2-induced migration and angiogenic sprouting at nanomolar concentrations (Xie et al., 2018). Its inhibition of the ERK pathway translates into decreased microvessel density in tumor xenografts and suppressed tumor vascularization. Compared to sunitinib and sorafenib, anlotinib shows higher selectivity for VEGFR2 and broader inhibition of angiogenic signaling (internal review).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 with an IC₅₀ of 5.6 ± 1.2 nM, PDGFRβ at 8.7 ± 3.4 nM, and FGFR1 at 11.7 ± 4.1 nM in in vitro kinase assays (Xie et al., 2018).
• In endothelial cell migration and tube formation assays, anlotinib demonstrates concentration-dependent inhibition, outperforming sunitinib, sorafenib, and nintedanib at equivalent doses (Xie et al., 2018).
• Oral bioavailability is 28–58% in rats and 41–77% in dogs, with high plasma protein binding (93%) and extensive tissue distribution, including the ability to cross the blood-brain barrier (APExBIO).
• The median lethal dose (LD₅₀) in 14-day oral rat studies is 1735.9 mg/kg, with mild systemic toxicity and no significant organ or genotoxicity observed (Xie et al., 2018).
• In vivo, anlotinib reduces tumor vascular density and can induce tumor regression in mouse xenograft models, outperforming standard-of-care TKIs in some systems (Xie et al., 2018).

This article provides a mechanistic and benchmarking update beyond prior reviews such as "Rewiring Tumor Angiogenesis Research" by offering direct cross-comparison of IC₅₀ data and pharmacokinetic parameters. For an expanded discussion of workflow design, see "Optimizing Angiogenesis Assays"; this present article focuses on molecular selectivity and translational limits. For systems-level strategy and clinical context, "Unraveling Tumor Angiogenesis" examines broader translational implications.

Applications, Limits & Misconceptions

Recommended Applications:

• Cell-based assays of endothelial migration, viability, and tube formation (e.g., using EA.hy 926 or HUVEC lines).
• In vivo tumor angiogenesis and vascular density quantification in xenograft models.
• Signaling pathway studies involving ERK/Akt modulation downstream of VEGFR2/PDGFRβ/FGFR1.
• Pharmacokinetic studies of multi-target TKIs in preclinical species.

Common Pitfalls or Misconceptions

• Direct tumor cytotoxicity is limited in vitro: Micromolar concentrations are required for direct tumor cell inhibition; anti-angiogenic activity occurs at lower (nanomolar) doses (Xie et al., 2018).
• Not for diagnostic or therapeutic use: Anlotinib (hydrochloride) from APExBIO is for research use only and is not validated for clinical or diagnostic applications (APExBIO).
• Genetic/organ toxicity minimal at research doses: Safety data support use in research settings; extrapolation to human therapy must be cautious (Xie et al., 2018).
• Requires proper storage: Product must be stored at -20°C to maintain stability (APExBIO).
• Assay readouts are context-specific: Experimental results can vary by cell type, matrix, and growth factor stimulation regimen.

Workflow Integration & Parameters

Anlotinib (hydrochloride) (SKU C8688, APExBIO) integrates into standard angiogenesis, migration, and viability assay workflows. For endothelial migration inhibition, recommended concentrations range from 1–100 nM. For tube formation and ERK pathway assays, titrate from 5–50 nM to establish dose-response. Anlotinib is compatible with most cell culture systems, requiring dissolution in DMSO (≤0.1% final concentration) and storage at -20°C. Preclinical PK studies support oral administration for animal models (bioavailability: 28–77%). Metabolic stability is ensured by CYP3A-mediated phase I metabolism, yielding hydroxylated and dealkylated metabolites. For experimental troubleshooting and reproducibility guidance, see scenario-driven protocols in "Scenario-Driven Solutions in Cancer Research".

Conclusion & Outlook

Anlotinib hydrochloride is a validated, multi-target tyrosine kinase inhibitor with robust anti-angiogenic activity and superior selectivity for VEGFR2, PDGFRβ, and FGFR1. Its favorable pharmacokinetic and safety profiles, as detailed in preclinical studies, recommend its use in advanced cancer and angiogenesis research. The C8688 kit from APExBIO provides a reliable, research-grade reagent for mechanistic and translational studies. Future research may explore clinical translation and combinatorial strategies with other targeted therapies.